Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ClinicalTrials.gov 24,857 recruiting now free trial finder

Find a clinical trial that's recruiting now

Search 24,857 actively recruiting US clinical trials by condition, drug, or state, each entry links straight to its NIH ClinicalTrials.gov record so you can check eligibility and contact the study team.

24,857
trials recruiting now
14%
of all US trials open to enrollment
52
states with recruiting sites

A trial is listed as recruiting when its sponsor has marked it open to new participants on the public registry. Type a condition or drug name (for example, "breast cancer" or "pembrolizumab") to narrow the list, and add a state to find studies with a site near you. Results are ordered with the most relevant recruiting studies first; each card shows the study phase and enrollment target, and opens the full record, including eligibility criteria and contact details, on ClinicalTrials.gov.

100 trials found

Recruiting 100,000 target

Protocol for Collecting, Banking and Distributing Human Tissue Samples: St. Jude Children's Research Hospital Tissue Resources Core Facility

St. Jude Children's Research Hospital

NCT01354002

Recruiting 100,000 target

Caris Biorepository Research Protocol

Caris Science

NCT01499394

Recruiting NA 100,000 target

Women Informed to Screen Depending on Measures of Risk (Wisdom Study)

University of California, San Francisco

NCT02620852

Recruiting 100,000 target

International Weight Control Registry

Tufts University

NCT04907396

Recruiting 40,000 target

Registry Study for Radiation Therapy Outcomes

Proton Collaborative Group

NCT01255748

Recruiting 30,000 target

Pennington Center Longitudinal Study (PCLS)

Pennington Biomedical Research Center

NCT00959270

Recruiting Phase 3 20,000 target

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

UMC Utrecht

NCT02735707

Recruiting 10,000 target

Sickle Cell Clinical Research and Intervention Program

St. Jude Children's Research Hospital

NCT02098863

Recruiting 10,000 target

Health Electronic Assessment of Risks and Trends Using Biometric Equipment and Technology

Tulane University

NCT06753045

Recruiting 10,000 target

Innovations in Genicular Outcomes Registry

Pacira Pharmaceuticals

NCT05495334

Recruiting NA 8,000 target

Nutrition for Precision Health, Powered by the All of Us

RTI International

NCT05701657

Recruiting 6,550 target

Non-Invasive Preeclampsia Screening and Biobank

Sequenom

NCT06643741

Recruiting Phase 3 6,000 target

BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies

Pfizer

NCT07160244

Recruiting 5,000 target

ARGONAUT: Stool and Blood Sample Bank for Cancer Patients

Persephone Biosciences

NCT04638751

Recruiting 5,000 target

International Registry for Men With Advanced Prostate Cancer (IRONMAN)

Prostate Cancer Clinical Trials Consortium

NCT03151629

Recruiting 5,000 target

Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)

HistoSonics

NCT06486454

Recruiting 5,000 target

Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature

Boston Scientific Corporation

NCT04674969

Recruiting 5,000 target

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

Duke University

NCT04278404

Recruiting 4,490 target

Observational Study Protocol: LIVER-R

AstraZeneca

NCT06252753

Recruiting Phase 3 4,390 target

A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)

Merck Sharp & Dohme

NCT07044297

Recruiting NA 4,000 target

The Fourth Left Atrial Appendage Occlusion Study

Hamilton Health Sciences Corporation

NCT05963698

Recruiting Phase 3 4,000 target

AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia

University of Manitoba

NCT05848713

Recruiting Phase 3 4,000 target

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49

Vaxcyte

NCT07284654

Recruiting Phase 3 3,200 target

Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

Icahn School of Medicine at Mount Sinai

NCT04045665

Recruiting 3,110 target

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

Mayo Clinic

NCT05051722

Recruiting 3,000 target

Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry

Duke University

NCT01915511

Recruiting 3,000 target

Real World Registry for Use of the Ion Endoluminal System

Intuitive Surgical

NCT06004440

Recruiting 3,000 target

Pennington Generation Cohort

Pennington Biomedical Research Center

NCT06849206

Recruiting 3,000 target

Pulmonary Hypertension Association Registry

Pulmonary Hypertension Association

NCT04071327

Recruiting Phase 3 2,400 target

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Merck Sharp & Dohme

NCT06966700

Recruiting 2,400 target

Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier

Veracyte

NCT06426628

Recruiting NA 2,400 target

Motiva Implants® Post-Approval Study

Motiva USA

NCT06938399

Recruiting 2,150 target

CORCYM Mitral, Aortic aNd Tricuspid Post-maRket Study in a reAl-world Setting

Corcym S.r.l

NCT05002543

Recruiting 2,020 target

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Guardant Health

NCT05059444

Recruiting NA 2,009 target

LITES Task Order 0005 Prehospital Airway Control Trial (PACT)

Jason Sperry

NCT04100564

Recruiting Phase 3 2,000 target

Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction

Uppsala University

NCT02901184

Recruiting 2,000 target

Endovascular AAA Intervention Using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis

W.L.Gore & Associates

NCT06218875

Recruiting 2,000 target

Black and African Americans Connections to Parkinson's Disease (BLAAC PD)

Michael J. Fox Foundation for Parkinson's Research

NCT06719583

Recruiting 2,000 target

Pancreatic Cancer Detection Consortium

City of Hope Medical Center

NCT06388967

Recruiting NA 2,000 target

Microbial Cell-free Metagenomic Sequencing for Suspected Infections in Adult Immunocompromised Outpatients

Karius

NCT07110636

Recruiting NA 1,850 target

Evaluation of Are You Ready?

The Policy & Research Group

NCT06580080

Recruiting Phase 4 1,710 target

LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women

Insud Pharma

NCT05303636

Recruiting Phase 3 1,700 target

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

Boehringer Ingelheim

NCT06238622

Recruiting Phase 3 1,700 target

Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

Kailera

NCT07284901

Recruiting 1,650 target

Prospective Study to Assess a Diagnostic Aid for Cancer

Harbinger Health

NCT07046260

Recruiting 1,600 target

Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study

M.D. Anderson Cancer Center

NCT06651580

Recruiting Phase 3 1,590 target

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

Janssen Research & Development

NCT05552222

Recruiting NA 1,500 target

Evaluation of Unstained

The Policy & Research Group

NCT06574139

Recruiting 1,500 target

Spinal Cord Injury Registry - North American Clinical Trials Network

Robert G. Grossman, MD

NCT00178724

Recruiting Phase 3 1,500 target

A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)

Colorado Prevention Center

NCT06024746

Recruiting 1,500 target

Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain

Boston Scientific Corporation

NCT06827262

Recruiting 1,500 target

Complex Adult Deformity Surgery (CADS)

International Spine Study Group Foundation

NCT04194138

Recruiting Phase 2 1,500 target

Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

Sparrow Pharmaceuticals

NCT07296484

Recruiting 1,500 target

Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease

Incyte Corporation

NCT05919511

Recruiting NA 1,400 target

Evaluation of Peer Group Connection - Middle School

The Policy & Research Group

NCT06582641

Recruiting Phase 3 1,310 target

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

Merck Sharp & Dohme

NCT06136624

Recruiting Phase 3 1,300 target

A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows

Ipsen

NCT07435428

Recruiting 1,300 target

Collection of Samples USOPTIVAL Study

Universal Diagnostics

NCT04792684

Recruiting Phase 2 1,280 target

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Global Coalition for Adaptive Research

NCT03970447

Recruiting Phase 3 1,280 target

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

Novo Nordisk A/S

NCT07207811

Recruiting Phase 3 1,220 target

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

AstraZeneca

NCT06921785

Recruiting Phase 3 1,200 target

Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

Kailera

NCT07284979

Recruiting Phase 3 1,200 target

A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

Eli Lilly and Company

NCT06993792

Recruiting Phase 4 1,200 target

Refining Treatment Options for Trichomonas Vaginalis Infection: A Comparative Analysis of Metronidazole and Secnidazole

Tulane University

NCT06261840

Recruiting Phase 3 1,200 target

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Merck Sharp & Dohme

NCT06312176

Recruiting Phase 2 1,200 target

Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation

Regeneron Pharmaceuticals

NCT07175428

Recruiting Phase 3 1,200 target

Evaluation of a New Strategy for Protocolized Antibiotic Care for Severe Open Fractures: SEXTANT

Major Extremity Trauma Research Consortium

NCT04678154

Recruiting NA 1,176 target

Blood Pressure Lowering Strategies to Eliminate Hypertension Disparities (BLESSED)

Tulane University

NCT06133322

Recruiting Phase 3 1,123 target

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

Merck Sharp & Dohme

NCT06952504

Recruiting Phase 3 1,100 target

Trauma Resuscitation With Low-Titer Group O Whole Blood or Products

University of Alabama at Birmingham

NCT05638581

Recruiting Phase 4 1,094 target

A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations

ModernaTX

NCT06585241

Recruiting Phase 3 1,023 target

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

Merck Sharp & Dohme

NCT07216703

Recruiting 1,000 target

Abbott DBS Post-Market Study of Outcomes for Indications Over Time

Abbott Medical Devices

NCT04071847

Recruiting 1,000 target

DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

United Therapeutics

NCT06388421

Recruiting NA 1,000 target

Clinical Validation of the Aptitude Medical Systems Metrix COVID-19 Test

Aptitude Medical Systems

NCT06744660

Recruiting NA 1,000 target

Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.

Pacific Edge Limited

NCT06394869

Recruiting NA 1,000 target

Pivotal, Prospective, Multi-centre, Single-arm Study to Evaluate the Safety and Effectiveness of Oli for Identification of Patients, During the Intrapartum Period, Who Are at Higher Risk of Developing Abnormal Postpartum Uterine Bleeding, Including Postpartum Haemorrhage

Baymatob Operations Pty

NCT06655207

Recruiting 1,000 target

Global Paradise System US Post Approval Study

ReCor Medical

NCT06297291

Recruiting Phase 3 1,000 target

Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children

Philip Spinella

NCT06070350

Recruiting NA 1,000 target

A Randomized Comparison of Personalized Therapy Mgmt Based On Coronary Atherosclerotic Plaque Vs. Usual Care for Symptomatic Patients With Suspicion of CAD

Cleerly

NCT06713239

Recruiting Phase 3 990 target

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine

Merz Therapeutics

NCT07018700

Recruiting Phase 2 956 target

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

BicycleTx Limited

NCT06225596

Recruiting Phase 3 944 target

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

Pfizer

NCT05020236

Recruiting NA 900 target

Hybrid Type I Effectiveness-Implementation Trial of a Social Network Support Intervention

University of Chicago

NCT05723653

Recruiting NA 900 target

The Dose Trial: Dose Intensity of Behavioral Interventions for Childhood Obesity

Vanderbilt University Medical Center

NCT06654323

Recruiting Phase 3 895 target

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

AstraZeneca

NCT04862663

Recruiting Phase 3 892 target

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

GlaxoSmithKline

NCT05855200

Recruiting NA 842 target

CTSN Embolic Protection Trial

Icahn School of Medicine at Mount Sinai

NCT06027788

Recruiting Phase 4 832 target

A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations

ModernaTX

NCT07089706

Recruiting Phase 3 810 target

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Celgene

NCT05519085

Recruiting NA 806 target

Church-based Health Intervention to Eliminate Racial Inequalities in Cardiovascular Health

Tulane University

NCT06065098

Recruiting Phase 3 800 target

Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

AstraZeneca

NCT06079671

Recruiting Phase 3 800 target

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Eli Lilly and Company

NCT07369011

Recruiting NA 800 target

Intervention to Prevent Behavioral Health Symptoms Among Pandemic Affected Children

University of Illinois at Urbana-Champaign

NCT05639465

Recruiting 800 target

Myriad™ Augmented Soft Tissue Reconstruction Registry

Aroa Biosurgery Limited

NCT05243966

Recruiting Phase 3 800 target

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

Janssen Research & Development

NCT07225946

Recruiting Phase 1 796 target

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

DualityBio

NCT05150691

Recruiting Phase 3 795 target

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

Janssen Research & Development

NCT06208150

Recruiting Phase 3 780 target

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

BeiGene

NCT05100862

Recruiting Phase 3 780 target

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

Merz Therapeutics

NCT07018713

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Recruiting status is reported by each study's sponsor and mirrored from the public registry. Always confirm current eligibility and status on ClinicalTrials.gov before contacting a study.

Verify with NIH →